Biochemists Develop New Way to Control Cell Biology with Light

Scientists at the University of Alberta have developed a new method of controlling biology at the cellular level using light. The tool–called a photocleavable protein–breaks into two pieces when exposed to light, allowing scientists to study and manipulate activity inside cells in new and different ways.

First, scientists use the photocleavable protein to link cellular proteins to inhibitors, preventing the cellular proteins from performing their usual function. This process is known as caging.

“By shining light into the cell, we can cause the photocleavable protein to break, removing the inhibitor and uncaging the protein within the cell,” said lead author Robert Campbell, Ph.D., professor in the Department of Chemistry. Once the protein is uncaged, it can start to perform its normal function inside the cell.

The tool is relatively easy to use and widely applicable for other research that involves controlling processes inside a cell, according to the Investigators.

The power of light-sensitive proteins, Dr. Campbell explained, is that they can be used to study the inner workings of any living cell. For example, optogenetic tools are widely used to activate brain activity in mice.

“We could use the photocleavable protein to study single bacteria, yeast, human cells in the lab or even whole animals such as zebrafish or mice,” he continued. “To put these proteins inside an animal, we simply splice the gene for the protein into DNA and insert it into the cells using established techniques.”

The gene for the photocleavable will be made available on Addgene, a nonprofit organization established to make it easier for scientists to share plasmids.

“We want to provide new ways to learn about cell biology,” said Dr. Campbell. “I see countless potential applications for research and future investigation—from looking at which cells become which tissues in development biology to investigating the possibilities of gene-editing technology.”

The research (“Optogenetic Control with a Photocleavable Protein, PhoCl”) was published in Nature Methods.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客